# US 2022/0010292 A1 · Method for the generation of compact tale-nucleases and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0010292 A1
- Document ID: US20220010292A1
- Status: Published application
- Kind: A1
- Application number: 17/489,454
- Filed: 2021-09-29
- Published: 2022-01-13
- Earliest claimed: 2011-04-05
- Assignees: Cellectis
- Applicants: Cellectis
- Inventors: Philippe Duchateau; Julien Valton; Claudia Bertonati; Jean-Charles Epinat; George H. Silva; Alexandre Juillerat; Marine Beurdeley
- Web page: https://patentgrep.com/patent/US20220010292A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/195: from bacteria
- C12N 5/0602: {Vertebrate cells}
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 9/16: acting on ester bonds (3.1)
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 14/4703: {Inhibitors; Suppressors}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/07: containing a mitochondrial localisation signal
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C12P 19/34: Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The present invention relates to a method for the generation of compact Transcription Activator-Like Effector Nucleases (TALENs) that can efficiently target and process double-stranded DNA. More specifically, the present invention concerns a method for the creation of TALENs that consist of a single TALE DNA binding domain fused to at least one catalytic domain such that the active entity is composed of a single polypeptide chain for simple and efficient vectorization and does not require dimerization to target a specific single double-stranded DNA target sequence of interest and process DNA nearby the DNA target sequence. The present invention also relates to compact TALENs, vectors, compositions and kits used to implement the method.

## Claims

### Claim at position 1

1-77. (canceled)

### Claim 78

A compact Transcription Activator-Like Effector Nuclease (TALEN) monomer that cleaves a DNA target sequence of interest comprising:
(i) one core TALE scaffold comprising Repeat Variable Dipeptide regions (RVDs) designed to target a binding site on said DNA target sequence of interest; and
(ii) at least one engineered single chain meganuclease variant comprising at least two LAGLIDADG homing endonuclease core domains designed to target a binding site on said DNA target sequence of interest, wherein the single chain meganuclease variant is fused to the C- and/or N-terminus of said core TALE scaffold; and
wherein the targeted binding site of the TALE DNA scaffold and the targeted binding site of the meganuclease variant homing endonuclease core domains are separated by 12-40 bases.

### Claim 79 (depends on 78)

The compact TALEN monomer of claim 78, wherein said single chain meganuclease variant is fused to the C-terminus of said core TALE scaffold.

### Claim 80 (depends on 78)

The compact TALEN monomer of claim 78, wherein said single chain meganuclease variant is fused to the N-terminus of said core TALE scaffold.

### Claim 81 (depends on 78)

The compact TALEN monomer of claim 78, wherein said single chain meganuclease variant has at least 95% sequence identity with SEQ ID NO: 1.

### Claim 82 (depends on 78)

The compact TALEN monomer of claim 78, wherein said core TALE scaffold comprises a protein sequence having at least 90% amino acid sequence identity with a protein sequence selected from the group consisting of SEQ ID NO: 134 and SEQ ID NO: 135.

### Claim 83 (depends on 78)

The compact TALEN monomer of claim 78, wherein said core TALE scaffold comprises a protein sequence having at least 90% amino acid sequence identity with a protein sequence selected from the group consisting of SEQ ID NO: 136 to SEQ ID NO: 139.

### Claim 84 (depends on 78)

The compact TALEN monomer of claim 78, wherein said compact TALEN monomer is designed to target a sequence in a T cell receptor gene.

### Claim 85 (depends on 78)

The compact TALEN monomer of claim 78, wherein said compact TALEN monomer comprises a protein sequence having at least 90% amino acid sequence identity with a protein sequence selected from the group of SEQ ID NO: 444-446.

### Claim 86 (depends on 78)

The compact TALEN monomer of claim 78, wherein said single chain meganuclease variant is fused to the C-terminus of said core TALE scaffold with a peptide linker.

### Claim 87 (depends on 78)

The method of claim 78, wherein the DNA target sequence of interest comprises SEQ ID NO: 290.

### Claim 88

A compact TALEN monomer that cleaves a DNA target sequence of interest comprising:
(i) one core TALE scaffold comprising Repeat Variable Dipeptide regions (RVDs) designed to target a binding site on said DNA target sequence of interest; and
(ii) at least one engineered single chain CreI meganuclease variant that has at least 90% identity with SEQ ID NO:291 and is designed to target a binding site on said DNA target sequence of interest fused to the C- and/or N-terminus of said core TALE scaffold; and
wherein the targeted binding site of the TALE DNA binding domain and the targeted binding site of the meganuclease variant binding domain are separated by 12-40 bases.

### Claim 89 (depends on 88)

The compact TALEN monomer of claim 88, wherein said single chain meganuclease variant is fused to the C-terminus of said core TALE scaffold.

### Claim 90 (depends on 88)

The compact TALEN monomer of claim 88, wherein said single chain meganuclease variant is fused to the N-terminus of said core TALE scaffold.

### Claim 91 (depends on 88)

The compact TALEN monomer of claim 88, wherein said single chain meganuclease variant has at least 95% sequence identity with SEQ ID NO: 1.

### Claim 92 (depends on 88)

The compact TALEN monomer of claim 88, wherein said core TALE scaffold comprises a protein sequence having at least 80% amino acid sequence identity with a protein sequence selected from the group consisting of SEQ ID NO: 134 and SEQ ID NO: 135.

### Claim 93 (depends on 88)

The compact TALEN monomer of claim 88, wherein said core TALE scaffold comprises a protein sequence having at least 80% amino acid sequence identity with a protein sequence selected from the group consisting of SEQ ID NO: 136 to SEQ ID NO: 139.

### Claim 94 (depends on 88)

The compact TALEN monomer of claim 88, wherein said compact TALEN monomer comprises a protein sequence having at least 90% amino acid sequence identity with a protein sequence selected from the group of SEQ ID NO: 444-446.

### Claim 95 (depends on 88)

The compact TALEN monomer of claim 88, wherein said single chain meganuclease variant is fused to the C-terminus of said core TALE scaffold with a peptide linker.
